363pa Pilot Study to Investigate Factors to Predict the Effect of Fulvestrant 500mg Treatment in Postmenopausal Patients with Tam or Ai-resistant Estrogen Receptor Positive Breast Cancer.
نویسندگان
چکیده
Aim: Fulvestrant (FUL) has been used to treat postmenopausal women with hormone receptor-positive metastatic or recurrent breast cancer after the failure of treatment attempts with tamoxifen (TAM) or aromatase inhibitor (AI). The factors predicting the outcome of treatment by FUL have not yet been identified. We retrospectively investigated our experience in an attempt to determine possible predictive factors of FUL treatment.
منابع مشابه
Relation between Estrogen and Progesterone Receptor Status with p53, Ki67 and Her-2 Markers in Patients with Breast Cancer
Background: Breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. Assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. The purpose of this study was to determine the relationship between estrogen and progesterone receptors with Her-2, Ki67, P53, and clinicopathologica...
متن کاملNew cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will be valuable tools to unravel the resistance mechanisms and to find new treatments and biomarkers...
متن کاملAdditive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Blocking estrogen receptors with antiestrogens and blocking estrogen synthesis with aromatase inhibitors are two strategies currently being used for reducing the effect of estrogen in postmenopausal estrogen receptor-positive breast cancer patients. To optimize these treatment strategies, we have investigated whether tumor progression can be delayed by combining the pure antiestrogen fulvestran...
متن کاملImaging features of estrogen-negative breast cancers: a correlation study with human epidermal growth factor type II overexpression
Background: Estrogen-negative breast cancers have different clinical course, prognostic features and treatment response in comparison to estrogen receptor-positive (ER-positive) breast cancers. Human epidermal growth factor receptor 2 (HER2) oncoprotein has found to have a pivotal role in natural cell growth and cell division and is suggested to be directly related to tumor invasiveness in brea...
متن کاملLow-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
PURPOSE Low-molecular-weight cyclin E (LMW-E) in breast cancer cells induces genomic instability and resistance to inhibition by p21, p27, and fulvestrant therapy. Here, we sought to determine if LMW-E renders breast cancer cells unresponsive to aromatase inhibitors (AI), elucidate the mechanism of such resistance, and ascertain if inhibitors of LMW-E-associated kinase activity could overcome t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014